A Study of MEDI-575 in Patients With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).
Advanced Solid Malignancies
DRUG: MEDI-575
Safety and tolerability assessed primarily by adverse events including abnormal values of clinical laboratory test, ECG and vital sign, 30 days after the last dose of MEDI-575
Pharmacokinetic variables of MEDI-575 by assessment of drug concentrations in serum after intravenous infusion, 30 days after last dose of study drug|To evaluate the immunogenicity of MEDI-575 by measuring anti-MEDI-575 antibodies, 3 months after last dose of study drug|Anti-tumor activity of MEDI-575 using Response Evaluation Criteria in Solid Tumors (RECIST), 3 months after last dose of study drug
The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).